The company has announced that a new formulation patent for the drug candidate cobitolimod has been granted by the European Patent Office.
The patent provides protection of the enema formulation of cobitolimod, that is currently under evaluation in the ongoing phase III program CONCLUDE. The patent will provide an exclusivity period until September 2042, with the possibility of up to 5 years extension upon market approval.
“We are pleased that this important patent has been granted by the European Patent Office,” says Jenny Sundqvist, CEO of InDex Pharmaceuticals. “It is a key component in our robust patent portfolio for cobitolimod as it specifically protects the intended commercial product and provides broader protection than a method of use patent.”
InDex Pharmaceuticals has filed corresponding patent applications in additional strategically important territories around the world.